Scientists Find Gene That Protects Against Colon Cancer

A genetic variant that millions of people carry without knowing it could be the key to preventing one of the deadliest cancers.

Scientists at Wayne State University and the Karmanos Cancer Institute have confirmed that a natural mutation called TGFBR1*6A significantly reduces the risk of colorectal cancer. About 14% of people worldwide carry this genetic variation, which acts like built-in armor against the disease.

The discovery marks the end of a 30-year scientific journey. Dr. Boris Pasche first identified the mutation in the late 1990s, but standard genetic testing tools kept missing it because the DNA region was too complex to read accurately.

To solve this mystery, researchers created specially engineered mice carrying the human version of the gene. The mice with TGFBR1*6A developed far fewer precancerous polyps and tumors than those without it.

The protective effect proved even stronger in human studies. Working with the Colon Cancer Family Registry, researchers analyzed data from families across the United States, Canada, and Australia. People carrying the mutation showed consistently lower cancer rates, especially those already at high risk due to family history or inherited conditions like familial adenomatous polyposis.

That last finding matters tremendously. FAP patients typically develop hundreds of polyps that turn cancerous by age 40 without intervention. For these families, knowing about TGFBR1*6A status could inform treatment decisions and surveillance schedules.

The Ripple Effect

This research changes how we think about cancer prevention. Standard genome testing has overlooked TGFBR1*6A for years, meaning millions of people don't know they carry natural protection.

Now that scientists can accurately detect the mutation, doctors may eventually use this information to personalize cancer screening. Someone with the protective gene might need less frequent colonoscopies, while those without it could benefit from earlier or more intensive monitoring.

The discovery also opens doors for new treatments. Understanding why TGFBR1*6A protects cells could help researchers develop therapies that mimic its effects for everyone, not just natural carriers.

Colorectal cancer remains the third most common cancer in America, affecting about 150,000 people annually. Any tool that helps identify who needs extra protection and who already has it could save thousands of lives.

Sometimes the best medicine is the one we're born with.